Bruker (NASDAQ:BRKR) Issues Earnings Results, Misses Expectations By $0.01 EPS

Bruker (NASDAQ:BRKR) released its quarterly earnings results on Tuesday. The medical research company reported $0.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.61 by ($0.01), Briefing.com reports. The firm had revenue of $864.40 million for the quarter, compared to analysts’ expectations of $866.46 million. Bruker had a return on equity of 24.92% and a net margin of 11.29%. The business’s quarterly revenue was up 16.4% on a year-over-year basis. During the same period last year, the firm earned $0.74 EPS. Bruker updated its FY 2024 guidance to 2.360-2.410 EPS and its FY24 guidance to $2.36-2.41 EPS.

Bruker Stock Performance

Shares of Bruker stock traded down $2.35 during trading on Wednesday, reaching $58.99. The company’s stock had a trading volume of 464,763 shares, compared to its average volume of 1,064,424. The firm has a market cap of $8.93 billion, a price-to-earnings ratio of 24.64, a price-to-earnings-growth ratio of 2.32 and a beta of 1.20. Bruker has a one year low of $54.55 and a one year high of $94.86. The business’s fifty day moving average price is $64.08 and its 200-day moving average price is $66.56. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.75 and a current ratio of 1.65.

Bruker Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, September 16th. Shareholders of record on Monday, September 2nd were issued a dividend of $0.05 per share. The ex-dividend date of this dividend was Friday, August 30th. This represents a $0.20 annualized dividend and a yield of 0.34%. Bruker’s dividend payout ratio (DPR) is presently 8.30%.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. TD Cowen dropped their target price on Bruker from $74.00 to $72.00 and set a “hold” rating on the stock in a research report on Wednesday, August 7th. Barclays lowered their price objective on Bruker from $75.00 to $69.00 and set an “overweight” rating for the company in a research note on Wednesday. Citigroup cut their price objective on shares of Bruker from $95.00 to $80.00 and set a “buy” rating on the stock in a research note on Wednesday, July 10th. Wells Fargo & Company cut their price target on shares of Bruker from $78.00 to $75.00 and set an “overweight” rating for the company in a report on Wednesday. Finally, Wolfe Research cut shares of Bruker from an “outperform” rating to a “peer perform” rating in a report on Monday, September 30th. One analyst has rated the stock with a sell rating, four have issued a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $80.00.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.